Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPC1063 open-label extension in moderate to severe ulcerative colitis
NL-OMON53026Phase 3Completed
- Sponsor
- Shanghai Celgen Biopharma
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ozanimod in autoimmune colitis, sponsored by Shanghai Celgen Biopharma. Primary endpoints: Proportion of patients in clinical remission, Proportion of patients with a clinical response and 15 more. Started Nov 2016; status: completed.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON53026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53026.